Stock REGN REGENERON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Delayed Nasdaq
Other stock markets
 03:57:16 2024-05-14 pm EDT 		5-day change 1st Jan Change
985.7 USD +0.89% Intraday chart for Regeneron Pharmaceuticals, Inc. +1.62% +12.23%
May. 13 Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Younger CRSwNP Group DJ
May. 13 Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Dupixent Supplemental Application for Priority Review MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Younger CRSwNP Group
DJ
Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Dupixent Supplemental Application for Priority Review
MT
The Interplay: Key Decisions At The Intersection Of Antitrust & Life Sciences - April 2024
AQ
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
GL
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
AQ
REGENERON PHARMACEUTICALS - LATEST DB-OTO RESULTS SHOW DRAMATICALLY IMPROVED HEARING TO NORMAL LEVELS IN A CHILD WITH PROFOUND GENETIC DEAFNESS WITHIN 24 WEEKS AND INITIAL HEARING IMPROVEMENTS IN A SECOND CHILD AT 6 WEEKS
AQ
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
GL
Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
CI
UBS Raises Regeneron Pharmaceuticals Price Target to $1,124 From $1,099, Maintains Buy Rating
MT
Regeneron Announces Investor Conference Presentations
GL
Deutsche Bank Adjusts Price Target on Regeneron Pharmaceuticals to $870 From $880, Hold Rating Kept
MT
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,126
MT
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,183 From $1,177
MT
Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $1,000.25 From $1,016
MT
RBC Cuts Price Target on Regeneron Pharmaceuticals to $1,185 From $1,189
MT
Global markets live: Etsy, Qualcomm, Carvana, Rio Tinto, Apple...
Our Logo
Sector Update: Health Care Stocks Mixed Premarket Thursday
MT
Regeneron Pharmaceuticals : May 2024 Corporate Presentation
PU
Transcript : Regeneron Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024
Regeneron: Adjusted EPS down 4% in Q1
CF
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. REGN Stock
  4. News Regeneron Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW